Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
Author(s) -
Andrew J. PiperVallillo,
Meghan J. Mooradian,
Catherine B. Meador,
Beow Y. Yeap,
Jennifer Peterson,
Mustafa Sakhi,
Andrew Do,
Leyre Zubiri,
Sara E. Stevens,
Jeanne Vaughn,
Kelly Goodwin,
Alexander Gavralidis,
Henning Willers,
Adam M. Miller,
Anna F. Farago,
Zofia Piotrowska,
W. Marston Linehan,
Ibiayi DagogoJack,
Inga T. Lennes,
Lecia V. Sequist,
Jennifer S. Temel,
Rebecca S. Heist,
Subba R. Digumarthy,
Kerry L. Reynolds,
Justin F. Gainor
Publication year - 2020
Publication title -
jto clinical and research reports
Language(s) - English
Resource type - Journals
ISSN - 2666-3643
DOI - 10.1016/j.jtocrr.2020.100124
Subject(s) - medicine , population , lung cancer , incidence (geometry) , pneumonia , cumulative incidence , cancer , disease , cohort , physics , environmental health , optics
Lung cancer is associated with severe COVID-19 infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms, differential diagnosis, and outcomes of COVID-19 in lung cancer patients. Methods To determine an at-risk population for COVID-19, we retrospectively identified lung cancer patients receiving longitudinal care within a single institution in the 12 months (4/1/19 – 3/31/20) immediately preceding the COVID-19 pandemic, including an “active therapy population” treated within the last 60 days of this period. Among patients subsequently referred for COVID-19 testing, we compared symptoms, laboratory/radiographic findings, and outcomes of positive versus negative patients. Results Between 4/1/2019-3/31/2020, 696 patients received longitudinal care, including 406 (58%) in the active therapy population. Among 55 patients referred for COVID-19 testing, 24 (44%) were COVID-19 positive, representing a cumulative incidence of 3.4% (longitudinal population) and 1.5% (active therapy population). Compared to COVID-19-negative patients, COVID-19-positive patients were more likely to have a supplemental oxygen requirement (11% vs. 54%, p=0.005) and to have typical COVID-19 pneumonia imaging findings (5 vs. 56%, p=0.001). Otherwise, there were no significant differences in presenting symptoms. Among COVID-negative patients, alternative etiologies included treatment-related toxicity (26%), atypical pneumonia (22%), and disease progression (22%). Sixteen COVID-19-postive patients (67%) required hospitalization, and 7 (29%) died from COVID-related complications. Conclusions COVID-19 was infrequent in this lung cancer population, but these patients experienced high rates of morbidity and mortality. Oncologists should maintain a low threshold for COVID-19 testing in lung cancer patients presenting with acute symptoms.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom